A Comparison of Remimazolam versus Propofol on Blood Pressure Changes During Therapeutic Endoscopic Retrograde Cholangiopancreatography: A Randomized Controlled Trial
Primary result · Change in MAP after inductionResult — go to the resultMedian difference 17.0 mm Hg 95% CI 12.0–22.0Authors' conclusion
Remimazolam may be considered as an alternative to propofol for general anesthesia during therapeutic ERCP procedures, with the potential advantage of stable hemodynamics.
Study context
- Population
- Adults scheduled for elective therapeutic endoscopic retrograde cholangiopancreatography (ERCP)
- Participants
- 40 vs 40
- Comparison
- Remimazolam vs propofol anaesthesia
- Remimazolamn = 40
- Propofoln = 40reference
- Primary endpoint
- Change in mean arterial pressure (MAP) during induction and area under the baseline (AUB; BP below baseline × duration) throughout the procedure
Primary result
Change in MAP after induction
Median difference
17.0 mm Hg
95% CI 12.0–22.0
P < 0.001
Change by group
Remimazolam
−7.5
range −14.0–0 · mm Hg
Propofol
−25.0
range −33.8–-14.3 · mm Hg
Remimazolam vs Propofol
median difference 17.0 mm Hg (95% CI 12.0–22.0); P < 0.001
As reported in the abstract
Further findings
mm Hg·min
| Outcome | Remimazolam | Propofol | Median difference (mm Hg·min) (95% CI) | P value | |
|---|---|---|---|---|---|
| AUB throughout the procedure (co-primary) | −373 (range −82–-854) | −705 (range −272–-1100) | 255 (29–477) | P = 0.021 | |
| −2000200400600Difference, mm Hg·min (linear scale) |
Hypotension (MAP <65 mm Hg for ≥1 min)
P = 0.006
Safety
Events
| Outcome | Remimazolam | Propofol |
|---|---|---|
| Serious adverse events | 0 | 0 |
Original publication
A Comparison of Remimazolam versus Propofol on Blood Pressure Changes During Therapeutic Endoscopic Retrograde Cholangiopancreatography: A Randomized Controlled Trial. Anesth Analg. Published 25 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →